The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City and Wichita, the University of Kansas-Lawrence, and the Stowers Institute for Medical Research (via consortium agreement). In 2010, 143 members of KUCC accounted for $11.4 million of NCI funding and a total of $55.1 million in overall cancer-related funding. KUCC is led by Roy A. Jensen, M.D. who is supported by a strong, nationally recognized leadership team. Over the last seven years substantial progress has been made securing institutional commitment, recruiting key leadership positions, building nationally significant research programs, developing our clinical research program, improving and expanding our facilities, and creating transdisciplinary and collaborative interactions. With input from our External Advisory Board, we have established three goals for KUCC that will insure we make a national impact in the fight against cancer: Goal 1: Become the leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies. Goal 2: Provide the optimal environment for basic, translational, clinical, and population-based research in oncology by developing and fostering a collaborative, collegial, and dynamic culture of scientific inquiry. Goal 3: Be a nationally recognized leader in partnering with community oncologists and other key stakeholders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout our service area. To accomplish these goals KUCC has four research programs including: Cancer Biology, Cancer Control and Population Health, Cancer Prevention, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, the Cancer Center supports four shared resources: Biostatistics and Informatics, Lead Development and Optimization, Biospecimen, and Clinical Trials Management.

Public Health Relevance

KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. We hope to establish an NCI-designated cancer center to meet the needs of the more than five million Americans who live within the 120,000 square miles of our catchment area.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Schools of Medicine
Kansas City
United States
Zip Code
Jiang, Yu; Simon, Steve; Mayo, Matthew S et al. (2015) Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors. Stat Med 34:613-29
Zeineldin, Maged; Jensen, Derek; Paranjape, Smita R et al. (2014) Human cancer xenografts in outbred nude mice can be confounded by polymorphisms in a modifier of tumorigenesis. Genetics 197:1365-76
Winham, Stacey J; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Genet Epidemiol 38:457-66
Block, Matthew S; Charbonneau, Bridget; Vierkant, Robert A et al. (2014) Variation in NF-?B signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 23:1421-7
Pessetto, Ziyan Y; Ma, Yan; Hirst, Jeff J et al. (2014) Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther 13:2276-87
Purrington, Kristen S; Slager, Susan; Eccles, Diana et al. (2014) Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35:1012-9
Bohl, Christopher R; Harihar, Sitaram; Denning, Warren L et al. (2014) Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med (Berl) 92:13-30
Peterson, Kenneth R; Costa, Flávia C; Fedosyuk, Halyna et al. (2014) A cell-based high-throughput screen for novel chemical inducers of fetal hemoglobin for treatment of hemoglobinopathies. PLoS One 9:e107006
Meneely, Kathleen M; Luo, Qianyi; Riley, Andrew P et al. (2014) Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorg Med Chem 22:5961-9
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256

Showing the most recent 10 out of 26 publications